U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 200 points during on Monday. The Dow traded down 0.55% to 42,079.06 while the NASDAQ rose 0.14% to 18,144.66. The S&P 500 also fell, dropping, 0.14% to 5,730.18. Check This Out: How To Earn $500 A Month From McCormick Stock Ahead Of Q3 Earnings Leading and Lagging Sectors Consumer staples shares jumped by 0.3% on Monday. In trading on Monday, materials shares fell by 0.6%. Top Headline The Chicago PMI rose to 46.6 in ...

On Monday, Prime Medicine Inc. PRME announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co BMY to develop reagents for the next generation of ex vivo T-cell therapies. Under the terms of the agreement, Prime Medicine will design optimized Prime Editor reagents for a select number of targets, including reagents that use its Prime Assisted Site-Specific Integrase Gene Editing (PASSIGE) technology. Also Read: Preclinical-Phase Firm Prime Medicine's Gene Editing Platfo ...

Financial Performance - Net loss for Q2 2024 was $55.3 million, compared to a net loss of $42.4 million in Q2 2023, indicating a 30% increase in losses[6]. - R&D expenses for Q2 2024 were $43.1 million, up from $34.6 million in Q2 2023, reflecting a 24% increase driven by pipeline advancement[5]. - G&A expenses for Q2 2024 were $12.6 million, compared to $10.7 million in Q2 2023, representing an 18% increase[5]. - Cash position as of June 30, 2024, was $176.4 million, up from $135.2 million as of December 31, 2023, showing a 30% increase[6]. - Prime Medicine's total assets as of June 30, 2024, were $259.7 million, compared to $193.9 million as of December 31, 2023[13]. - The weighted-average common shares outstanding increased to 119,188,866 in Q2 2024 from 90,467,298 in Q2 2023[14]. Clinical Development - Prime Medicine received FDA clearance to advance PM359 for chronic granulomatous disease into clinical trials, with initial clinical data expected in 2025[2]. - The company plans to establish proof-of-concept for Shielded Hematopoietic Stem Cell and Immunotherapy Pairs technology in 2024[4]. - Prime Medicine aims to initiate IND-enabling activities for at least one liver program in 2024, targeting IND or clinical trial application in H2 2025 or H1 2026[4]. - The company is advancing its differentiated CAR-T program using PASSIGE technology into lead optimization[4].

Prime Medicines (PRME) has made encouraging pipeline progress of late and investors will focus on related updates when it reports second-quarter 2024 results next month. Surprise - Reported Earnings Histor The Zacks Consensus Estimate for loss per share in the second quarter is pinned at 40 cents. | --- | --- | --- | --- | --- | |----------------------|----------------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | Magnitude Consensus Estimate Trend (60 Days) | | | | | | ...

Prime Medicine, Inc.'s (PRME) shares have risen 16.4% in the past three months compared with the industry's growth of 10.9%. The stock has also outperformed the sector and the S&P 500. PRME Outperforms Industry, Sector & S&P 500 Prime Medicine is deploying its proprietary gene editing technology, Prime Editing platform, to develop a new class of differentiated one-time curative genetic therapies. While the approach is interesting, the company's ability to have sufficient cash leeway to conduct its R&D progr ...

Shares of Prime Medicine, Inc. (PRME) have gained 24.1% over the past four weeks to close the last trading session at $6.54, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.45 indicates a potential upside of 121%. The average comprises 11 short-term price targets ranging from a low of $9 to a high of $21, with a standard deviation of $4.34. While the lowest estimate indicate ...

Shares of Prime Medicine, Inc. (PRME) have gained 18% over the past four weeks to close the last trading session at $6.42, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $15 indicates a potential upside of 133.6%. They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with ...

CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Financial Officer of Prime Medicine, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, 2024, at 4:30 p.m. ET in New York, NY. A live audio webcast of the fireside chat will be availabl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q OR (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission file number 001-41536 Prime Medicine, Inc. (Exact name of registrant as specified in its charter) (State ...

Exhibit 99.1 "In 2024, we expect to bring the first-ever Prime Editing-based product candidate to patients, while continuing to strengthen our modular Prime Editing platform and advance our next wave of programs across a range of target tissues," said Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine. "In recent months, we made meaningful progress toward this goal. In April, the U.S. Food and Drug Administration (FDA) cleared our investigational new drug (IND) application for ...